Peptide laws in China

How China regulates medicines

Medicines in China are regulated under the Drug Administration Law and its implementing regulations, administered by the National Medical Products Administration (NMPA). The State Council issued a fourth revision of the Regulations for the Implementation of the Drug Administration Law as Order No. 828, signed on January 16, 2026 and in force from May 15, 2026 ¹. It runs to nine chapters and 89 articles and covers research, registration, manufacture, distribution, online sale, hospital pharmacy and penalties ¹.

A drug must be registered with the NMPA before it can be manufactured or sold. That is the pivot for everything below: an approved peptide medicine is a prescription drug with a registered label, and anything else is an unregistered drug.

The May 2026 rules on online sales and online prescribing

Two articles of the revised regulations matter most for peptides bought online. Article 46 provides that specially managed drugs, naming vaccines, blood products, narcotic drugs, psychotropic drugs, medicinal toxic drugs, radioactive drugs and drug precursor chemicals, may not be sold through the internet at all, and that other drugs carrying higher medication risk may not be sold by online retail, with the specific catalogue to be set by the NMPA ¹. Article 51 closes the matching door on the prescribing side: a doctor may not issue a prescription for the drugs covered by article 46 during online medical consultation ¹.

Article 79 makes selling drugs online in breach of article 46 a punishable violation ¹. Reporting in the Chinese press described the practical effect from May 15: platforms tightened or withdrew listings for GLP-1 injections sold for weight loss, since injectables other than glucose-lowering products sit on the existing prohibition catalogue, and pharmacies were reported to require prescriptions matching the product, dose and strength being bought ². We did not find an NMPA document naming GLP-1 drugs specifically, and this page does not claim one exists.

Approved GLP-1 medicines

Semaglutide has been approved in China for type 2 diabetes for several years, and in June 2024 the NMPA approved it for long-term weight management, marketed in China under a separate Chinese brand name, for adults with a body mass index of 30 or more, or 27 to 30 with at least one weight-related condition ³. Tirzepatide followed for weight management ³.

The patent position changed in 2026. Novo Nordisk's core Chinese compound patent on semaglutide expired on March 20, 2026, and more than ten domestic manufacturers have filed generic or modified-version applications that are now in NMPA review; none had been approved as of the reporting we read ⁴. If and when they are approved, they will be registered prescription medicines, not a route to unregulated supply.

Research peptides

Research peptides such as BPC-157, TB-500 and retatrutide are not approved medicines in China, and we found no NMPA statement specific to them, so this page does not describe one ⁵. China is a major manufacturing base for peptide chemicals sold internationally as research material, which is a manufacturing and export question rather than a Chinese approval; our manufacturing guide covers how such material is made and what analyses have found in it.

For anyone in China, the practical point is the same as elsewhere: a substance with no NMPA registration has no approved indication, no approved label and no assured quality, and the drug law's offences attach to manufacturing and selling unregistered drugs.

Bringing medicines into China

Article 48 of the regulations allows individuals to carry or post small quantities of medicines into China, limited to a reasonable quantity for their own use and subject to the national rules on personal items entering the country ¹. Article 47 is a separate route: a hospital may apply to import a small quantity of a drug for urgent clinical need, which the NMPA decides after consulting the health authorities ¹. Neither provision is a licence to import unregistered peptides.

Sport

Chinese athletes are subject to the WADA Prohibited List through the China Anti-Doping Agency. BPC-157 is caught by the S0 catch-all, and growth hormone secretagogues and releasing peptides are named under S2.2.4 ⁵. Our WADA hub lists each peptide and section.

China in context

The 2026 Chinese rules fit a pattern we track across jurisdictions: regulators tightening the supply route rather than the drug itself. Japan's health ministry issued notices on off-label GLP-1 use in June 2026, Thailand made injectable GLP-1 medicines specially controlled from September 2026, and the UK and EU have acted on advertising and online supply. Our Japan page, Thailand page and legal overview set those out.

Questions to check

• Is the medicine registered with the NMPA, and for the indication being offered?
• Is an online seller offering an injectable medicine that may not be sold by online retail?
• Was the prescription written in a proper consultation, not an online one for a restricted drug?
• Am I importing within the personal-use limits of article 48?
• Am I subject to anti-doping rules?

The bottom line

China's revised drug regulations, in force since May 15, 2026, cut off online retail and online prescribing for higher-risk medicines, which is the route GLP-1 injections had been reaching weight-loss buyers through. Semaglutide is approved for diabetes and for weight management, its Chinese patent has expired, and generics are in review. Research peptides remain unregistered drugs.

Frequently asked questions

Are peptides legal in China?

Approved peptide medicines, such as semaglutide, are prescription drugs. Research peptides such as BPC-157 are not registered medicines in China.

Can you buy GLP-1 injections online in China?

The regulations in force since May 15, 2026 bar online retail of higher-risk drugs and online prescribing of them; reporting describes platforms tightening GLP-1 listings as a result.

Is semaglutide approved in China for weight loss?

Yes. The NMPA approved it for long-term weight management in June 2024, under a separate Chinese brand name.

Is generic semaglutide available in China?

The core Chinese patent expired on March 20, 2026 and applications are under NMPA review; approvals had not been reported when we checked.

Can I post peptides to China for personal use?

Article 48 limits personal carriage and posting of medicines to a reasonable quantity for one's own use under the personal-items rules; it does not legalise unregistered drugs.

Related on Grey Peptides

• Peptide laws in Japan
• Peptide laws in Thailand
• Legal Status Checker

Sources

1. State Council of the People's Republic of China. Regulations for the Implementation of the Drug Administration Law, Order No. 828 (signed January 16, 2026; in force May 15, 2026), articles 45 to 48, 51 and 79. Read in Chinese October 3, 2026. gov.cn
2. Chinese press reporting on the regulations in force (Jiemian via Sina Finance, May 18, 2026; 21st Century Business Herald, June 5, 2026; Shenzhen Special Zone Daily, June 14, 2026) describing platforms restricting GLP-1 listings and pharmacies requiring matching prescriptions. Read October 3, 2026.
3. Reporting of the NMPA's June 2024 approval of semaglutide for long-term weight management in China (Fierce Pharma; Yicai Global), including the BMI criteria and the separate Chinese brand name. Read October 3, 2026. NMPA's own site refused our requests (HTTP 412).
4. Reporting of the March 20, 2026 expiry of Novo Nordisk's core Chinese semaglutide patent (CN200680006674.6) and of generic applications filed with the NMPA (VCBeat; industry analyses). Read October 3, 2026.
5. Grey Peptides encyclopedia and WADA hub: no approval recorded for BPC-157, TB-500 or retatrutide in any jurisdiction we track; WADA sections S0 and S2.2.4. Read October 3, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.